

## 普罗帕酮对麻醉兔左心室后负荷变化引起的电生理改变的影响

邱汉婴<sup>1</sup>, 李迪俊, 毛焕元<sup>2</sup> (汕头医科大学附属二院心血管疾病研究室, 汕头 515031, 中国;  
<sup>2</sup>同济医科大学心血管疾病研究所, 武汉市 430022, 中国)

**Effects of propafenone on electrophysiologic changes caused by alteration of left ventricular afterload in anesthetized rabbits**

QIU Han-Ying<sup>1</sup>, LI Di-Jun, MAO Huan-Yuan<sup>2</sup>  
 (Cardiovascular Division, Second Affiliated Hospital of Shantou University Medical College, Shantou 515031, China; <sup>2</sup>Institute of Cardiovascular Diseases, Tongji Medical University, Wuhan 430022, China)

**KEY WORDS** left ventricular dysfunction; ventricular outflow obstruction; ventricular pressure; electrophysiology; ventricular fibrillation; propafenone; nitroprusside

**AIM:** To study effects of propafenone (Pro) on ventricular electrophysiologic changes caused by alteration of left ventricular afterload of rabbit heart. **METHODS:** Before and after iv Pro 3 mg·kg<sup>-1</sup>, changing afterload of left ventricle (LV), occurrence of ventricular arrhythmia, left ventricular diastolic thresholds (VDT), relative refractory period (RRP), effective refractory period (ERP), dispersion of refractory period, and ventricular fibrillation threshold (VFT) were recorded. **RESULTS:** Increasing afterload of LV increased temporal dispersion of RRP and ERP [from 11 ± 4 and 6 ± 3 ms to 18 ± 8 and 13 ± 8 ms (+ ΔP = 8.4 ± 2.9 kPa) individually (*P* < 0.05)] and decreased VFT [from 5.5 ± 1.0 V to 3.9 ± 0.9 V (*P* < 0.01)]; Ventricular arrhythmia was seen in all rabbits. But reducing left ventricular afterload did not alter the electrophysiologic parameters in LV and did not induce ventricular arrhythmia. Pro iv prolonged RRP and ERP, increased VDT and VFT (*P* < 0.01); Increasing or decreasing left ventricular afterload did not cause much alteration of ventricular electrophysiologic parameters (*P* > 0.05). **CONCLUSION:** Pro inhibited increase of dispersion of

refractory period and decrease of VFT caused by increase of left ventricular afterload and has an effect of anti-ventricular arrhythmia.

**关键词** <sup>心律失常</sup>左室功能障碍; 心室流出道梗阻; 心室压力; 电生理学; 心室纤颤; 普罗帕酮; 硝普盐

**目的:** 探讨普罗帕酮 (Pro) 对兔左心室后负荷变化引起的心室电生理改变的作用。 **方法:** Pro 3 mg·kg<sup>-1</sup> iv 前后, 改变左心室后负荷, 观察室性心律失常发生情况; 并测定左心室舒张阈值 (VDT), 相对不应期 (RRP), 有效不应期 (ERP) 及其不应期离散和心室纤颤阈 (VFT)。 **结果:** 增加左心室后负荷 (B 级), 可使左室 RRP 和 ERP 时间离散增加, VFT 降低, 并出现室性心律失常。 Pro iv 后, VDT, RRP, ERP, VFT 均较用药前显著延长或升高 (*P* < 0.01); 改变左室后负荷, 心室电生理参数无显著改变 (*P* > 0.05)。 **结论:** Pro 可抑制左室后负荷增加引起的不应期离散增大和 VFT 降低, 起到抗室性心律失常的作用。

心室机械负荷变化引起的心室电生理变化 (收缩兴奋反馈或称机械电反馈) 是导致室性心律失常发生的原因之一。增加左室容量可引起心室 relative refractory period (RRP) 和 effective refractory period (ERP) 缩短、ERP 离散增大, 并引发室性心律失常<sup>[1,2]</sup>。但心室后负荷增加是否能引起心室电生理参数改变, 诱发室性心律失常及抗心律失常药物对其的作用, 国内外均未见报道<sup>[3,4]</sup>。本文在静注普罗帕酮前后, 通过改变在体兔左心室后负荷, 观察了心室电生理参数的变化特征及其与室性心律失常发生的关系, 以期为心脏负荷改变引起的室性心律失常的抗心律失常治疗, 提供理论依据。

### MATERIALS AND METHODS

改变在体兔左心室后负荷<sup>[5]</sup> 大耳白兔 9 只, 同济医

<sup>1</sup> Phn 86-754-827-4004, ext 3083. Fax 86-754-842-3575

Received 1997-01-24

Accepted 1997-06-17

科大学实验动物学部提供, 1级, 其中♂ 4只, ♀ 5只, 体重  $2.2 \pm 0.3$  kg, 戊巴比妥钠  $30 \text{ mg} \cdot \text{kg}^{-1}$ , iv 麻醉, 胸骨左缘开胸, 保持自主呼吸, 维持窦性节律; 左侧颈动脉切开、左心室内插管, 连接 TP-400T 型压力换能器测定左室内压力。采用自制兔主动脉缩窄夹(缩窄环直径分别为 1.5 mm 和 2.5 mm), 机械性地部分夹闭主动脉根部, 分级(A, B级)增加左心室后负荷。另使用 PFA-05 型输液泵控制性地输注血管扩张剂硝普钠(北京制药工业研究所实验药厂出品, 5% 葡萄糖 500 mL + 硝普钠 50 mg), 通过降低动脉压, 分级(C, D级)减小左心室后负荷。左心室后负荷变化用左心室收缩期压力变化值  $\pm \Delta P$  kPa 表示。

**测定左心室电生理参数** 将自制四极心肌插入电极插入左心耳右下缘室间沟左室侧, 电极下缘位于左室心尖部。四极电极极间距离: 第 1-2 极, 第 3-4 极均为 1.5 mm, 第 2-3 极为 10 mm。根据测定的左室电生理参数不同, 将第 1-2 或第 3-4 极作为刺激电极, 相应其余两个电极作为记录电极。连接 SEC-3102 型刺激器, 分别测定 a, b 两部位的心室舒张阈值(VDT)、相对不应期(RRP)和有效不应期(ERP)或将第 2-3 极作为刺激电极, 相应其余两个电极作为记录电极, 连接 DF-3A 型刺激器, 测定室颤阈(VFT)。VDT, RRP, ERP, VFT 的测定参照文献<sup>[6]</sup>。将左心室壁 a, b 两部位(a, 左室前壁; b, 左室心尖部)测得的 RRP 及 ERP 的最大差值分别定为 RRP 及 ERP 离散<sup>[7]</sup>。VFT 的测定在每次测 VDT, RRP 和 ERP 后进行, 致颤参数: 脉宽 10 ms, 周期 30 ms, 脉冲发放持续时间 1 s。实验通过 RM-6000 型多导生理仪示波观察并记录资料。Pro (广州明光制药厂出品, 每支含  $3.5 \text{ g} \cdot \text{L}^{-1}$ 、用生理盐水稀释 1 倍)  $3 \text{ mg} \cdot \text{kg}^{-1}$  iv 前和用药 20 min 后<sup>[8]</sup>、分别在改变左心室后负荷前, 部分夹闭主动脉增加左心室后负荷时、除去对主动脉夹闭及输注硝普钠、控制性减小左心室后负荷时、测定左心室电生理参数。

**统计学处理** 实验结果用配对 *t* 检验处理。

## RESULTS

逐级增加左心室后负荷(B级,  $+\Delta P = 8.4 \pm 2.9$  kPa)可使左室空间 RRP 离散和 ERP 离散分别从  $11 \pm 4$  和  $6 \pm 3$  ms 增加到  $18 \pm 8$  和  $13 \pm 8$  ms ( $P < 0.05$ ), VFT 从  $5.5 \pm 1.0$  V 降低到  $3.9 \pm 0.8$  V ( $P < 0.01$ ), 各实验动物均出现室性心律失常; 而逐级减小左室后负荷(C级,  $-\Delta P = 2.5 \pm 0.8$  kPa; D级,  $-\Delta P = 5.1 \pm 1.1$  kPa)、心室电生理各参数无变化( $P > 0.05$ ), 各实验动物亦无室性心律失常发生。静注普罗帕酮后, VDT, RRP, ERP, VFT 均较用药前显著延长或升高( $P < 0.01$ ); 逐级增加

或逐级减小左室后负荷, 心室电生理参数无显著改变( $P > 0.05$ ), 各实验动物均未发生室性心律失常(Tab 1)。

## DISCUSSION

在在体动物心脏, Franz 等和 Dean 等<sup>[3,4]</sup> 发现, 减小左室后负荷, 动作电位时程延长, 而增加左室后负荷可使动作电位时程缩短, 并出现早期后除极。Reiter 亦发现<sup>[2]</sup>、增加左室容量引起左室 ERP 缩短, 但右室不应期无变化, 使左、右心室空间 ERP 离散增大; 另外, 左室 ERP 缩短亦有区域性不均一性。本研究增加左心室后负荷使左室空间 RRP 离散和 ERP 离散增加结果与文献报道<sup>[2]</sup> 相一致。导致上述电生理变化的可能机制是: 改变左室负荷, 改变心室所受到的牵张程度, 可导致心肌电缆性质和电容的变化, 对心肌牵张程度的改变可导致肌膜对离子通透性改变, 但其确切机制还不甚清楚, 但可能与牵张依赖性离子通道的存在及特性有关<sup>[9]</sup>。Todt 等发现, Pro 能延长心室不应期<sup>[10]</sup>。且本研究首次发现, 对于增加左心室后负荷引起的左室空间 RRP 和 ERP 离散增加, 亦可通过 Pro 加以抑制。上述作用可能与 Pro 阻断通道, 延长心室不应期有关<sup>[10]</sup>。

## REFERENCES

- Lerman BB, Burkhoff D, Yue DT, Sagawa K. Mechano-electrical feed-back: independent role of preload and contractility in modulation of canine ventricular excitability. *J Clin Invest* 1985; 76: 1843-50.
- Reiter MJ, Synhorst DP, Mann DE. Electrophysiological effects of acute ventricular dilatation in the isolated rabbit heart. *Circ Res* 1988; 62: 554-62.
- Franz MR, Burkhoff D, Yue DT, Sagawa K. Mechanically induced action potential changes and arrhythmia in isolated and in situ canine hearts. *Cardiovasc Res* 1989; 23: 213-23.
- Dean JW, Lab MJ. Effect of changes in load on monophasic action potential and segment length in pig heart in situ. *Cardiovasc Res* 1989; 23: 887-96.
- Qiu HY, Mao HY, Cao LS, Li DJ. Experimental study of spatial limitation of ventricular inhibition by subthreshold conditioning stimulation in the rabbit. *Chin J Pathophysiol* 1993; 9: 140-3.
- Qiu HY, Wei TX, Zhang YR, Yan XF, Wei JH. Effects of ranitidine on ventricular refractory period and fibrillation threshold of normal and ischemic ventricle in rabbits. *Acta Pharmacol Sin* 1994; 14: 260-2.
- Yang XM, Zhao DH, Sheng BH. Effect of L-4-thiopropine on

Tab 1. Effect of Pro 3 mg·kg<sup>-1</sup> iv on electrophysiologic changes caused by alteration of left ventricular afterload. n = 9 rabbits,  $\bar{x} \pm s$ . Pre-drug: <sup>a</sup>P > 0.05, <sup>b</sup>P < 0.05, <sup>c</sup>P < 0.01 vs Pre-changing afterload; <sup>d</sup>P > 0.05 vs relaxation of clamping aorta; Post-drug: <sup>e</sup>P > 0.05 vs Pre-changing afterload; <sup>f</sup>P > 0.05 vs relaxation of clamping aorta; <sup>m</sup>P > 0.05, <sup>o</sup>P < 0.01 vs Pre-drug.  $\Delta P$  in LV (Pre-drug): A = 3.5 ± 1.7 kPa; B = 8.4 ± 2.9 kPa; C = -2.5 ± 0.8 kPa; D = -5.1 ± 1.1 kPa.  $\Delta P$  in LV (Post-drug): A = 3.5 ± 2.5 kPa; B = 6.5 ± 2.3 kPa; C = -2.7 ± 0.7 kPa; D = -4.7 ± 0.9 kPa.

		Pre-changing afterload in LV		Increasing afterload in LV (clamping aorta)		Release of clamping	Decreasing afterload in LV (nitroprusside iv drip)	
		$\Delta P$ in LV	0	A	B	0	C	D
VDT/V	Pre-drug	a	0.8 ± 0.3	0.8 ± 0.3 <sup>a</sup>	1.0 ± 0.3 <sup>a</sup>	0.8 ± 0.2	0.9 ± 0.3 <sup>d</sup>	1.0 ± 0.2 <sup>d</sup>
		b	0.8 ± 0.2	0.8 ± 0.2 <sup>a</sup>	0.8 ± 0.3 <sup>a</sup>	0.8 ± 0.2	0.9 ± 0.2 <sup>d</sup>	0.9 ± 0.3 <sup>d</sup>
	Post-drug	a	1.4 ± 0.6 <sup>o</sup>	1.3 ± 0.4 <sup>so</sup>	1.3 ± 0.4 <sup>so</sup>	1.3 ± 0.3 <sup>o</sup>	1.4 ± 0.3 <sup>o</sup>	1.4 ± 0.3 <sup>o</sup>
		b	1.4 ± 0.4 <sup>o</sup>	1.2 ± 0.4 <sup>so</sup>	1.3 ± 0.4 <sup>so</sup>	1.4 ± 0.4 <sup>o</sup>	1.3 ± 0.3 <sup>o</sup>	1.5 ± 0.3 <sup>o</sup>
	a - b	11 ± 4	10 ± 9 <sup>a</sup>	18 ± 8 <sup>b</sup>	7 ± 6	0.7 ± 6 <sup>d</sup>	8 ± 6 <sup>d</sup>	
	Post-drug	a	173 ± 20 <sup>o</sup>	170 ± 20 <sup>so</sup>	172 ± 16 <sup>so</sup>	178 ± 13 <sup>o</sup>	177 ± 13 <sup>o</sup>	180 ± 15 <sup>o</sup>
b		171 ± 23 <sup>o</sup>	167 ± 17 <sup>so</sup>	176 ± 11 <sup>so</sup>	176 ± 10 <sup>o</sup>	179 ± 15 <sup>o</sup>	179 ± 14 <sup>o</sup>	
a - b	9 ± 5 <sup>m</sup>	9 ± 5 <sup>sm</sup>	12 ± 9 <sup>sm</sup>	6 ± 3 <sup>m</sup>	8 ± 4 <sup>m</sup>	6 ± 4 <sup>m</sup>		
RRP/ms	Pre-drug	a	131 ± 4	134 ± 12 <sup>a</sup>	134 ± 16 <sup>a</sup>	141 ± 17	142 ± 14 <sup>d</sup>	146 ± 13 <sup>d</sup>
		b	131 ± 13	134 ± 17 <sup>a</sup>	140 ± 18 <sup>a</sup>	139 ± 17	141 ± 14 <sup>d</sup>	142 ± 12 <sup>d</sup>
	Post-drug	a	173 ± 20 <sup>o</sup>	170 ± 20 <sup>so</sup>	172 ± 16 <sup>so</sup>	178 ± 13 <sup>o</sup>	177 ± 13 <sup>o</sup>	180 ± 15 <sup>o</sup>
		b	171 ± 23 <sup>o</sup>	167 ± 17 <sup>so</sup>	176 ± 11 <sup>so</sup>	176 ± 10 <sup>o</sup>	179 ± 15 <sup>o</sup>	179 ± 14 <sup>o</sup>
	a - b	9 ± 5 <sup>m</sup>	9 ± 5 <sup>sm</sup>	12 ± 9 <sup>sm</sup>	6 ± 3 <sup>m</sup>	8 ± 4 <sup>m</sup>	6 ± 4 <sup>m</sup>	
	Post-drug	a	156 ± 19 <sup>o</sup>	155 ± 19 <sup>so</sup>	151 ± 19 <sup>so</sup>	162 ± 16 <sup>o</sup>	162 ± 18 <sup>o</sup>	163 ± 18 <sup>o</sup>
b		153 ± 25 <sup>o</sup>	156 ± 16 <sup>so</sup>	158 ± 14 <sup>so</sup>	160 ± 16 <sup>o</sup>	162 ± 16 <sup>o</sup>	162 ± 18 <sup>o</sup>	
a - b	8 ± 7 <sup>m</sup>	7 ± 6 <sup>sm</sup>	13 ± 11 <sup>sm</sup>	6 ± 0.3 <sup>m</sup>	5 ± 4 <sup>m</sup>	7 ± 4 <sup>m</sup>		
ERP/ms	Pre-drug	a	112 ± 9	117 ± 15 <sup>a</sup>	114 ± 16 <sup>a</sup>	124 ± 16	128 ± 15 <sup>d</sup>	132 ± 17 <sup>d</sup>
		b	115 ± 13	118 ± 16 <sup>a</sup>	121 ± 21 <sup>a</sup>	123 ± 13	130 ± 18 <sup>d</sup>	132 ± 18 <sup>d</sup>
a - b	6 ± 3	4 ± 3 <sup>a</sup>	13 ± 8 <sup>b</sup>	4 ± 3	3 ± 2 <sup>d</sup>	3 ± 2 <sup>d</sup>		
Post-drug	a	156 ± 19 <sup>o</sup>	155 ± 19 <sup>so</sup>	151 ± 19 <sup>so</sup>	162 ± 16 <sup>o</sup>	162 ± 18 <sup>o</sup>	163 ± 18 <sup>o</sup>	
	b	153 ± 25 <sup>o</sup>	156 ± 16 <sup>so</sup>	158 ± 14 <sup>so</sup>	160 ± 16 <sup>o</sup>	162 ± 16 <sup>o</sup>	162 ± 18 <sup>o</sup>	
a - b	8 ± 7 <sup>m</sup>	7 ± 6 <sup>sm</sup>	13 ± 11 <sup>sm</sup>	6 ± 0.3 <sup>m</sup>	5 ± 4 <sup>m</sup>	7 ± 4 <sup>m</sup>		
VFT/V	Pre-drug	a	5.5 ± 1.0	5.1 ± 0.6 <sup>a</sup>	3.9 ± 0.8 <sup>b</sup>	5.6 ± 1.0	5.5 ± 0.9 <sup>d</sup>	5.2 ± 1.0 <sup>d</sup>
		b	5.5 ± 1.0	5.1 ± 0.6 <sup>a</sup>	3.9 ± 0.8 <sup>b</sup>	5.6 ± 1.0	5.5 ± 0.9 <sup>d</sup>	5.2 ± 1.0 <sup>d</sup>
Post-drug	a	9.3 ± 1.8 <sup>o</sup>	8.4 ± 1.8 <sup>so</sup>	7.2 ± 1.6 <sup>so</sup>	9.3 ± 1.6 <sup>o</sup>	9.2 ± 1.8 <sup>o</sup>	9.2 ± 1.6 <sup>o</sup>	
	b	9.3 ± 1.8 <sup>o</sup>	8.4 ± 1.8 <sup>so</sup>	7.2 ± 1.6 <sup>so</sup>	9.3 ± 1.6 <sup>o</sup>	9.2 ± 1.8 <sup>o</sup>	9.2 ± 1.6 <sup>o</sup>	

arrhythmias caused by acute myocardial ischemia in rabbits. *Acta Pharmacol Sin* 1986; 7: 134-7.

8 Qiu HY, Mao HY, Li DJ. Effects of propafenone on changes of ventricular refractory period caused by subthreshold conditioning stimulation in the rabbit ventricle. *Chin Pharmacol Bull* 1993; 9: 301-4.

9 Craelius W, Chen V, El-Sherif N. Stretch activated ion channels in ventricular myocytes. *Biosci Rep* 1988; 8: 407-14.

10 Todt H, Krümpel G, Krejcy K, Raberger G. Mechanism of antiarrhythmic efficacy of propafenone as assessed by programmed electrical stimulation in conscious dogs. *J Cardiovasc Pharmacol* 1992; 19: 341-8.

### 1st International Symposium on Microdialysis in Drug Research and Development

1998 Apr 2 - 4

Noordwijkerhout, THE NETHERLANDS

Information: LACDR, Ms Flora Velthorst

P O Box 9502

2300 RA Leiden

THE NETHERLANDS

Phn 31-71-527-4341. Fax 31-71-527-4277. E-mail velthors@lacdr.leidenuniv.nl